Whitepapers


All series


All Whitepapers

The eye’s anatomy is highly resistant to penetration of therapeutic agents, and successfully bypassing its protective barriers requires in-depth knowledge of ocular delivery, as well as specialized formulation and development expertise. In this guide, we will discuss how new and existing technologies can be employed to optimize ophthalmic formulations. We will then review the top considerations for an ocular drug delivery project to maximize the probability of success.

To support the growing need for nitrosamine testing, SGS has expanded its volume for nitrosamine testing beyond its current service offering in Mississauga, Canada. SGS has added capacity and instrumentation to offer nitrosamine testing, including drug substance-related impurities (NDSRIs) at its West Chester, PA and Markham, Canada laboratories to allow for expanded capacity for nitrosamine testing, while staying ahead of the curve as regulations continue to evolve.

You can rely on Pfizer CentreOne as your CDMO for high-quality API synthesis, from process development through long-term supply. Our capabilities include complex organic synthesis, fermentation and bioprocessing up to 150,000-liter scale, milling and micronizing, process optimization and scale-up, and process industrialization.

Development of novel small molecule active pharmaceutical ingredients (APIs) is increasingly turned over to outsourced partners who have become the primary drivers of the product’s overall development and go-to-market strategy. With hundreds of potential partners that drug owners can choose from to develop and manufacture small molecule APIs, choosing the best partner can be a challenging task. In this white paper, we explore the importance of purposefully aligning the overall drug development strategy with a partnering strategy. We also review how increasing development of novel drugs are also impacting the industry’s go-to-market efforts, driving new demand for expert small molecule API suppliers. Finally, we consider how small molecule API development projects can be executed by leveraging the experience of embedded contract development and manufacturing (CDMO) partners.

To support the growing need for nitrosamine testing, SGS has expanded its volume for nitrosamine testing beyond its current service offering in Mississauga, Canada. SGS has added capacity and instrumentation to offer nitrosamine testing, including drug substance-related impurities (NDSRIs) at its West Chester, PA and Markham, Canada laboratories to allow for expanded capacity for nitrosamine testing, while staying ahead of the curve as regulations continue to evolve.

There has been a Growing concern among regulators driving a need for awareness for manufacturers to understand the risk associated with nitrosamines in pharmaceutical and biopharmaceutical products. In this session of Changing the Conversation with SGS Live, we tackled a variety of aspects of this important issue from the risk associated with nitrosamine contamination to discovery and mitigation of nitrosamine impurities. Our experts shared the current testing requirements, along with how SGS is helping drug manufacturers along the path of development to ensure their products are free from nitrosamine contamination.

If you want to learn more about the physical characterization of your pharmaceutical powders, download this free e-book. You will find real measurement data that has been collected from a range of characterization methods, including particle, surface area and pore size analysis, powder rheology, and X-ray diffraction. Deepening your understanding of bulk particle properties is just the first step to get more predictable formulations and optimized processes.

We offer a wide range analytical instrumentation to solve the most difficult characterization challenges like flowability, solubility, and consistency under real-life conditions. In this one-pager, which you can download below, you will find an overview of techniques as well as an explanation of which ones can be used for specific tasks (from sample identification to packaging and tableting).

Several parameters influence pharmaceutical powders. While research and development of drug formulation is highly dependent on material characteristics like purity and stability solubility, production deals with powder flow and packing and tableting processes. Furthermore, quality control ensures compliance and conducts elemental purity analysis. Understanding how to manage these parameters is the first step to optimizing your pharmaceutical powders and your final product

Any responsible business or industry takes quality seriously. It’s crucial to customer safety and satisfaction, and its prioritization in the development of healthcare products and services – especially pharmaceuticals – is obviously even more so. Nonetheless, it can be easy in development for smaller teams and companies to overlook some components of Quality, despite governmental requirements around complex quality initiatives. Those concerns are well-founded.

SGS has developed a network of centers of excellence for Nitrosamine testing across all regions to better serve our clients. Our experts specialize in method development solutions to identify and quantify all nitrosamine contaminants, including the challenging nitrosamine drug substance related impurities (NDSRIs).

The overall success of an organization is driven by the team that makes it. Many seek to create a culture of continuous improvement, but the path to get there is not always clear. Empowering employees and involving them in key decisions is vital in achieving an environment of operational excellence and strong company culture.